Amy Axel

Interleukin-6 induces an epithelial–mesenchymal transition phenotype in human breast cancer cells

Nicholas J. Sullivan, A. Kate Sasser, Amy Axel et al. · Oncogene · 2009 · 755 citations

Medicine, Cell Biology, Oncology +16

Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma

Saad Z. Usmani, Brendan M. Weiss, Torben Plesner et al. · Blood · 2016 · 404 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma

Inger S. Nijhof, Tineke Casneuf, Jeroen van Velzen et al. · Blood · 2016 · 380 citations · Full text

Life Sciences, Immunology, Oncology +13

Interleukin‐6 is a potent growth factor for ER‐α‐positive human breast cancer

A. Kate Sasser, Nicholas J. Sullivan, Adam Studebaker et al. · The FASEB Journal · 2007 · 227 citations

Medicine, Cell Biology, Oncology +17

Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma

Tineke Casneuf, Xu Steven Xu, Homer Adams et al. · Blood Advances · 2017 · 224 citations · Full text

Life Sciences, Immunology, Oncology +16